Why one compact binding domain can support a wider range of biologic designs
The conventional full-length IgG has long defined what an antibody medicine looks like.
It remains one of biotechnology’s most successful molecular formats, combining target recognition, bivalent binding, long serum exposure, Fc-mediated biology, and a well-established development path in a single molecule.
For many programs, that is exactly what the medicine needs.
But the antibody is no longer always the entire medicine.
It may be one recognition arm in a multispecific. It may direct a T cell through a CAR. It may carry a payload, be encoded by mRNA or AAV, or sit on a lipid nanoparticle to tell the vehicle where to go.
In these applications, the antibody is a component inside a larger therapeutic design.
That changes what the ideal component looks like.
In the first article of this series, The Discovery Engine Has Not Kept Up with the Medicine, we argued that the final modality should help determine the antibody format from the beginning. Single-domain antibodies are an important example of why that matters.
At approximately 12-15 kDa, a single-domain antibody, or sdAb, is about one-tenth the size of a conventional IgG. It is one independently functioning variable domain encoded by one compact sequence.
Its defining advantage is not simply that it is smaller.
It is that one domain can perform the complete binding function.
That architectural simplicity creates applications that larger or more assembly-dependent antibody formats do not always support as easily.
One domain changes the engineering problem
A full-length IgG depends on the expression and correct assembly of four polypeptide chains. A Fab is smaller, but its binding site still comes from paired heavy- and light-chain variable domains. An scFv places those two domains on one polypeptide but still relies on their orientation and a peptide linker.
Each format remains highly useful.
An sdAb starts from a different premise: the binder itself is one domain.
There is no light chain to pair and no VH-VL linker to optimize. One sequence corresponds to one binding unit.
That does not make every sdAb automatically stable, soluble, high-affinity, or developable. Those properties still need to be selected and tested.
But when a binder must be moved, fused, repeated, encoded, conjugated, or displayed, removing one layer of architectural dependency can matter.
Modularity: building complex biology from simple parts
The biology of a multispecific may be complicated.
The building blocks do not have to be.
sdAbs can be linked in tandem to create bispecific and multispecific constructs. They can be reordered, repeated to increase avidity, combined with Fc regions, or fused to enzymes, cytokines, receptors, and other functional modules.
Because each binding unit is self-contained, the design does not have to manage a separate light chain for every specificity. That can reduce pairing complexity and make more geometries practical to test.
Geometry still matters. Domain order, linker length, valency, epitope position, and spacing can determine whether a construct bridges two cells, clusters a receptor, blocks parallel pathways, or remains inactive until the right targets are present.
sdAbs do not answer those design questions automatically.
They provide a cleaner set of parts with which to explore them.
The same principle applies to multivalent formats. Repeating one domain can increase avidity against dense or repeating targets, while combining domains against different epitopes can create cooperative binding or reduce escape.
The molecule can become more complex without making each recognition unit more complex.
Cell therapy and immune engagement: a compact recognition domain
In a CAR, the antibody-derived binding domain is not a circulating drug.
It is the extracellular sensor of an engineered cell.
That sensor must be encoded within a larger receptor, expressed on the cell surface, and function in the geometry imposed by the CAR architecture. In many current designs, that role is performed by an scFv.
Single-domain antibodies provide another option.
Their compact architecture can simplify receptor construction and support tandem or multispecific CARs in which several recognition domains must fit within one genetic cassette. Fully human sdAbs can also provide human recognition domains without a separate humanization step.
The same modularity can support T-cell engagers and other immune-cell redirectors. One sdAb may recognize the disease target while another engages an immune receptor, with additional modules used to tune valency, half-life, or conditional activity.
Performance still depends on affinity, epitope, receptor spacing, antigen density, and signaling design.
The sdAb gives engineers a compact way to implement those biological choices.
Encoded biologics: when sequence length becomes a therapeutic property
The value of a one-domain binder becomes especially clear when the medicine is delivered as genetic information.
A conventional antibody requires separate heavy and light chains to be expressed in the same cell and assembled correctly. An sdAb can be encoded as one functional polypeptide from one compact coding sequence.
For mRNA medicines, that can simplify construct design and make it easier to encode multivalent or multispecific proteins within one open reading frame.
For AAV and other viral vectors, sequence space is limited. Every nucleotide used for the therapeutic protein competes with promoters, signal peptides, regulatory elements, and other components needed for expression.
A compact sdAb leaves more room for the rest of the cassette.
In these settings, sequence length is not merely convenient.
It is part of the therapeutic architecture.
Conjugates and targeted delivery: the antibody as an address
In an ADC or targeted delivery system, the binding domain has a defined job: recognize the destination and bring something else with it.
sdAbs can serve as compact targeting elements in drug conjugates, radionuclide conjugates, protein fusions, lipid nanoparticles, viral particles, and other delivery vehicles.
Their well-defined scaffold can support site-specific conjugation and controlled orientation when the appropriate residues, tags, or linkers are engineered into the molecule. Their limited footprint may also allow targeting ligands to be displayed without adding the mass of a full-length antibody.
This is particularly relevant for lipid nanoparticles.
Decorating an LNP with a cell-selective sdAb can give the particle an address beyond its default biodistribution. In principle, the same vehicle can be redirected toward a tumor antigen, an immune-cell subset, or another tissue marker by changing the targeting domain.
But a ligand does not solve delivery by itself. Density, orientation, circulation, protein corona formation, cellular uptake, and endosomal escape all influence whether the payload becomes active in the intended cell.
The sdAb provides the recognition module.
The vehicle still has to complete the journey.
Difficult targets: access depends on geometry
Affinity is not the only determinant of what an antibody can do.
The geometry of the binding surface also matters.
Conventional antibodies recognize antigens through a broad interface formed by paired heavy- and light-chain variable domains. That architecture is extraordinarily effective across many targets.
Some useful epitopes, however, are recessed, transient, conformational, or located close to a membrane.
The compact paratope of an sdAb can approach these surfaces differently. In several single-domain scaffolds, extended complementarity-determining loops can reach into clefts, pockets, and other constrained regions that may be difficult for a larger paired surface to engage.
This has made sdAbs valuable tools for conformationally dynamic membrane proteins, including GPCRs, and promising binders for ion channels and other difficult target classes. They can recognize extracellular loops, stabilize defined receptor states, or bind pore-adjacent and cryptic epitopes.
The advantage is not that every sdAb reaches every hidden site.
It is that the format expands the accessible epitope space.
When epitope determines mechanism, that can change the biology available to a program.
Tissue access: smaller molecules move differently
A 12-15 kDa binder distributes differently from a 150 kDa IgG.
sdAbs can diffuse rapidly through dense tissue and may penetrate solid tumors more evenly than larger antibodies, which can be slowed by size and high-affinity capture near the tumor periphery.
That can support therapeutic delivery, as well as support imaging.
Rapid tissue entry followed by fast clearance from the blood can create high target-to-background contrast sooner than a long-circulating IgG. The same pharmacokinetic profile that limits chronic systemic exposure can therefore benefit diagnostics, image-guided surgery, or short-duration targeting.
The blood-brain barrier requires more nuance.
Small size alone does not make an antibody brain-penetrant. Most proteins still require an active transport mechanism to cross efficiently.
But sdAbs can serve as compact brain-shuttle modules when selected against receptors that undergo transcytosis. The shuttle can be fused to a larger cargo and used to increase its central nervous system exposure.
The opportunity is not passive passage because the molecule is small.
It is the ability to build a compact transport module into a larger medicine.
Intracellular applications: reaching beyond the cell surface
Most therapeutic antibodies act outside the cell because conventional antibody fragments often do not fold or remain soluble in the reducing cytoplasm.
Some single-domain antibodies can function there.
When selected or engineered for intracellular stability, an sdAb can be expressed as an intrabody and bind a target in the compartment where it operates. It can inhibit an interaction, trap a protein in a location, report on a conformational state, or be fused to an effector that changes the target’s fate.
That creates potential access to transcription factors, signaling proteins, oncoproteins, viral proteins, and other intracellular targets that are difficult to approach with extracellular antibodies.
This capability is sequence-dependent. Intracellular candidates must be screened under the conditions in which they are expected to function.
But one genetically encoded domain provides a practical architecture for that search.
The addressable target space can move from the cell surface toward the intracellular proteome.
New routes of administration: bringing the binder to the disease
Full-length antibodies are usually administered by injection.
Their size, formulation requirements, and poor permeability across epithelial barriers make alternative routes difficult.
The compactness and robustness of some sdAbs can support local delivery strategies that are less practical for conventional antibodies.
Inhaled sdAbs can be delivered directly to the respiratory tract. Topical or ocular formats can place the binder at a disease surface. Orally administered sdAbs are also being developed for local action in the gastrointestinal tract, where formulation and protease stability can help the molecule reach intestinal targets.
Oral systemic delivery remains a much harder problem. An sdAb still faces gastric acid, digestive enzymes, mucus, and the epithelial barrier.
The opportunity is not that every sdAb can become a pill.
It is that the format can make selected local routes realistic enough to engineer.
The tradeoffs are part of the format
sdAbs are not miniature IgGs with every IgG property preserved.
They generally lack Fc-mediated functions unless an Fc or another immune-engaging module is added. Their small size can produce rapid renal clearance and short systemic half-life. A monovalent sdAb may need multimerization for the required avidity. Some sequences will need further engineering for solubility, stability, expression, or immunogenicity.
These are real constraints.
They are also design variables.
Half-life can be extended through Fc fusion, albumin binding, PEGylation, multimerization, or other approaches. Effector function can be added when the mechanism requires it. Rapid clearance can be retained for imaging or local therapy rather than engineered away.
The objective is not to make an sdAb behave exactly like an IgG.
It is to add the functions the application needs while preserving the advantages of the smaller binding unit.
Versatility is the point
The future of biologics will continue to depend on conventional full-length antibodies.
When a program needs long exposure, Fc biology, bivalent binding, and a deeply established development path, the IgG remains an exceptional format. Fabs, scFvs, and other fragments will remain important as well.
Single-domain antibodies occupy a distinct position within that landscape.
They offer one binding domain, one compact sequence, and a modular unit that can be linked, repeated, encoded, conjugated, displayed, transported, or expressed inside a cell.
That versatility supports a remarkable range of applications: multispecific antibodies, CARs and immune engagers, ADCs, mRNA and AAV medicines, targeted nanoparticles, difficult membrane proteins, imaging, brain delivery, intrabodies, and local administration.
The question is not whether the sdAb is universally better than every other antibody format.
It is whether its architecture is better matched to the medicine being built.
In the next article in this series, we will turn from the format to the discovery system and examine how Leveragen’s Singularity Suite is designed to generate sdAbs directly in vivo.
The molecule is smaller. What it enables is not.
